The Graeb Scale mark-up: Above shows the

schematic representation of the lateral ven-

tricles, the third and fourth ventricles, and tem-

oral and occipital horns. 

CLEAR-IVH is a Phase III randomized clinical trial (RCT) using recombinant tissue plasminogen activator (rtPA, Cathflo® Activase,® Genentech, Inc., San Francisco, CA) to treat subjects with intracerebral hemorrhage (ICH), intraventricular hemorrhage (IVH), and hydrocephalus.

The primary aim of the study is to determine whether rapid removal of IVH clot with low-dose rtPA more likely improves modified Rankin Scores at 6 months (Rankin 0-3) compared to subjects treated with best medical care alone.